Castle Biosciences initiated with bullish view at Guggenheim, here’s why

Guggenheim initiated coverage of Castle Biosciences with a Buy rating and $25 price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).